Best Cell & Gene Therapy CDMOs in Asia

· updated as new inspection, certificate, and trial data enters the platform

Cell & Gene Therapy manufacturers on CDMO Signal: 24 listed with manufacturing sites in Asia, 23 with a Signal Score. Together they have 30 FDA inspections on file (including 16 NAI, 11 VAI and 3 OAI), 6 FDA warning letters and 44 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Cell & Gene Therapy CDMOs in Asia with the most regulatory evidence on file

AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Biocon Biologics
75.7
Bengaluru, India
7 FDA inspections · 2 EMA/MHRA GMP certs
Last FDA inspection: 2025-09-03 · VAI
See the evidence →
Intas Pharmaceuticals
62.3
Ahmedabad, India
3 FDA inspections · 5 EMA/MHRA GMP certs
Last FDA inspection: 2025-09-16 · OAI
Warning letter 2026-03-30
See the evidence →
Minaris Advanced Therapies
83.1
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
3 FDA inspections · 4 EMA/MHRA GMP certs
Last FDA inspection: 2025-11-25 · NAI
See the evidence →
Pharmaron
86.9
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
5 FDA inspections · 1 EMA/MHRA GMP cert
Last FDA inspection: 2026-08-14 · NAI
See the evidence →
24
CDMOs tracked
23
Fully scored
10
With FDA records
30
FDA inspections
44
EMA/MHRA GMP certs
6
Warning letters

Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.

For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).

FDA inspection outcomes across these CDMOs: 16 NAI (no action), 11 VAI (voluntary action), 3 OAI (official action). Leading inspection & GMP sites: Denmark (23), India (13), United States (12), Germany (6), INDIA (5).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
2
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
3
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
83.1 99.2 3 insp · 4 GMP 2025-11-25 · NAI Limited —
4
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
5
LB
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
81.6 100.0 2 insp · 0 GMP 2026-09-18 · NAI — —
6
SG
Bengaluru, India
Hiring · 4 open roles
80.3 100.0 3 insp · 0 GMP 2025-02-20 · NAI — —
7
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
8
GZ
Indianapolis, IN · Lexington, MA
Hiring · 26 open roles
78.1 100.0 1 insp · 0 GMP 2025-08-27 · NAI Available —
9
BC
Bengaluru, India
Hiring · 48 open roles
75.7 93.1 7 insp · 2 GMP 2025-09-03 · VAI — —
10
PBI
Pennington, NJ · Nanjing, CN
64.0 — — None on file — —
11
HG
Yokohama, Japan
Also makes its own products
63.0 — — None on file — —
12
SM
Tokyo, JP
Also makes its own products
63.0 — — None on file — —
13
EA
Singapore, Singapore
63.0 — — None on file — —
14
IP
Ahmedabad, India
62.3 68.9 3 insp · 5 GMP 2025-09-16 · OAI
Warning letter 2026-03-30
— —
15
HX
Seoul, KR
Also makes its own products
59.0 — — None on file — —
16
CTP
Melbourne, Australia
59.0 — — None on file — —
17
SS
Bloomington, IN
59.0 — — None on file — —
18
TR
Kusatsu, Shiga Prefecture, Japan
57.9 — — None on file — 8 programs
19
UB
Shanghai, CN · Boston, MA
Hiring · 1 open role
56.5 — — None on file — —
20
GC
Yongin, KR
56.5 — — None on file — —
21
CH
56.5 — — None on file — —
—
Chongqing, China
Profiled — 1 insp · 0 GMP 2024-03-29 · NAI — —
How we score CDMOs →

What to evaluate in a Cell & Gene Therapy CDMO

Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

Cell & Gene Therapy CDMOs — Frequently Asked Questions

How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 10 Cell & Gene Therapy CDMOs with FDA inspection records and 44 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
The table on this page is the live list: the union of cell therapy, AAV, lentiviral, adenoviral, and gene-therapy-tagged manufacturers. This is the broadest advanced-therapy candidate list on the platform. CDMOs cannot pay to change a score.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Cell & Gene Therapy shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Cell Therapy CDMOs AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Viral Vector